The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Impact of chromosome 19p gene deletion on immunotherapy for NSCLC
Brian Henick, MD, Herbert Irving Comprehensive Cancer Center, New York, NY, explores the role of low-level copy number deletions of chromosome 19p genes such as STK11, KEAP1, and SMARCA4 in lung adenocarcinoma. Chromosome 19p deletions are associated with reduced immune infiltrates and decreased immune gene expression. Gains in the same chromosome, whilst rare, conversely correlated with improved benefit from immunotherapy. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
